BR112022010599A2 - Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina - Google Patents
Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-aminaInfo
- Publication number
- BR112022010599A2 BR112022010599A2 BR112022010599A BR112022010599A BR112022010599A2 BR 112022010599 A2 BR112022010599 A2 BR 112022010599A2 BR 112022010599 A BR112022010599 A BR 112022010599A BR 112022010599 A BR112022010599 A BR 112022010599A BR 112022010599 A2 BR112022010599 A2 BR 112022010599A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- methylbenzo
- oxetan
- chloropyridin
- dioxol
- Prior art date
Links
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 title abstract 3
- 239000011973 solid acid Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- SVPYZAJTWFQTSM-UGDMGKLASA-N 2-[[4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC=1C=CC(=NC=1)[C@@]1(OC2=C(O1)C=CC=C2C1CCN(CC1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)O)C SVPYZAJTWFQTSM-UGDMGKLASA-N 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FORMAS SÓLIDAS DE ÁCIDO 2-((4-((S)-2-(5- CLOROPIRIDIN-2-IL)-2-METILBENZO[D][1,3]DIOXOL-4-IL)PIPERIDIN1IL)METIL)-1-(((S)-OXETAN-2-IL)METIL)-1H-BENZO[D]IMIDAZOL-6- CARBOXÍLICO, SAL DE 1,3-DIHIDRÓXI-2-(HIDROXIMETIL)PROPAN2-AMIN. A presente invenção refere-se a formas sólidas de ácido 2-((4-((S)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((S)-oxetan-2-il)metil)-1H-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina, por exemplo, uma forma cristalina de hidrato (por exemplo, um mono-hidrato) (por exemplo, Forma 2 ou Forma 3) ou uma forma amorfa; bem como composições farmacêuticas, e usos das mesmas no tratamento de doenças, condições ou distúrbios modulados por GLP-1R em um mamífero, tal como um ser humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962946084P | 2019-12-10 | 2019-12-10 | |
PCT/IB2020/061585 WO2021116874A1 (en) | 2019-12-10 | 2020-12-07 | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022010599A2 true BR112022010599A2 (pt) | 2022-08-16 |
Family
ID=73835650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022010599A BR112022010599A2 (pt) | 2019-12-10 | 2020-12-07 | Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230045419A1 (pt) |
EP (1) | EP4073028A1 (pt) |
JP (1) | JP2021091683A (pt) |
KR (1) | KR20220112811A (pt) |
CN (1) | CN115175893A (pt) |
AR (1) | AR120703A1 (pt) |
AU (1) | AU2020402177A1 (pt) |
BR (1) | BR112022010599A2 (pt) |
CA (1) | CA3163979A1 (pt) |
MX (1) | MX2022007105A (pt) |
TW (1) | TWI809334B (pt) |
WO (1) | WO2021116874A1 (pt) |
ZA (1) | ZA202207589B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
CA3233131A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO2008012623A1 (en) * | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
PL2621493T3 (pl) | 2010-09-30 | 2017-01-31 | Pfizer Inc. | N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
SG11201804363UA (en) | 2015-12-29 | 2018-07-30 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
KR102314286B1 (ko) | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
-
2020
- 2020-12-07 BR BR112022010599A patent/BR112022010599A2/pt not_active Application Discontinuation
- 2020-12-07 AU AU2020402177A patent/AU2020402177A1/en active Pending
- 2020-12-07 KR KR1020227023147A patent/KR20220112811A/ko unknown
- 2020-12-07 WO PCT/IB2020/061585 patent/WO2021116874A1/en active Application Filing
- 2020-12-07 CA CA3163979A patent/CA3163979A1/en active Pending
- 2020-12-07 MX MX2022007105A patent/MX2022007105A/es unknown
- 2020-12-07 JP JP2020202383A patent/JP2021091683A/ja not_active Withdrawn
- 2020-12-07 CN CN202080095964.2A patent/CN115175893A/zh active Pending
- 2020-12-07 TW TW109143088A patent/TWI809334B/zh active
- 2020-12-07 EP EP20824663.7A patent/EP4073028A1/en active Pending
- 2020-12-07 US US17/782,478 patent/US20230045419A1/en active Pending
- 2020-12-09 AR ARP200103424A patent/AR120703A1/es unknown
-
2022
- 2022-07-08 ZA ZA2022/07589A patent/ZA202207589B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202136247A (zh) | 2021-10-01 |
TWI809334B (zh) | 2023-07-21 |
US20230045419A1 (en) | 2023-02-09 |
JP2021091683A (ja) | 2021-06-17 |
MX2022007105A (es) | 2022-07-11 |
AR120703A1 (es) | 2022-03-09 |
WO2021116874A1 (en) | 2021-06-17 |
CN115175893A (zh) | 2022-10-11 |
CA3163979A1 (en) | 2021-06-17 |
KR20220112811A (ko) | 2022-08-11 |
AU2020402177A1 (en) | 2022-06-16 |
EP4073028A1 (en) | 2022-10-19 |
ZA202207589B (en) | 2023-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022010599A2 (pt) | Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina | |
RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
BRPI0911035A2 (pt) | ativadores de pirrolidinona glicoquinase | |
NO20083572L (no) | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer | |
EA201290078A1 (ru) | Гетероциклические соединения для ингибирования pask | |
AR073348A1 (es) | Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
BR112014021634A8 (pt) | inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula | |
MX2010003346A (es) | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. | |
BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
PE20130281A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
BR112017010439A2 (pt) | composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto | |
MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
NO20090075L (no) | Nye CXCR2 inhibitorer | |
BR112017015852A2 (pt) | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 | |
NZ600390A (en) | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases | |
ECSP088473A (es) | FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB | |
BRPI0911476A2 (pt) | compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos | |
NO20064951L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse | |
PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
BR112015019754A2 (pt) | derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-(trifluoro-metil)bezil)quinazolin-4(3h)-ona e seu uso como inibidores de fosfoinositídeo 3-quinase | |
BR112021023054A2 (pt) | Formas cristalinas de um inibidor de btk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: PFIZER, INC. (US) |
|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |